First do no harm.
That’s a core principle for treating patients. But a promising gene-editing method called CRISPR-Cas9 could potentially harm patients. Two papers published in Nature Medicine on Monday raised concerns that using CRISPR-Cas9 to edit genes could increase the chances that cancer cells develop.
The stocks of CRISPR Therapeutics (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), and Intellia Therapeutics (NASDAQ:NTLA) plunged on the news. All three of these biotechs
are pioneering development of gene-editing therapies using CRISPR-Cas9.
But should investors....More>>>